{"id":127385,"date":"2026-07-11T00:42:12","date_gmt":"2026-07-11T00:42:12","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/127385\/"},"modified":"2026-07-11T00:42:12","modified_gmt":"2026-07-11T00:42:12","slug":"is-pfizer-on-track-to-launch-its-next-lipitor-this-time-in-the-weight-loss-market","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/127385\/","title":{"rendered":"Is Pfizer on Track to Launch Its Next Lipitor &#8212; This Time in the Weight-Loss Market?"},"content":{"rendered":"<p>Key Points<\/p>\n<p>Pfizer has regrouped in the GLP-1 space and is now working on a long-acting drug option.<\/p>\n<p>The company&#8217;s update on the drug&#8217;s development progress suggests it can compete with GLP-1 drugs from Eli Lilly and Novo Nordisk.<\/p>\n<p>Humans are very bad at taking medications. By some estimates, adherence to long-term chronic medication treatment plans is only around 50%. This is a big issue for GLP-1 weight-loss drugs, which must be taken for life and as often as daily. Pfizer (NYSE: PFE) is betting that making a more convenient option will give it a leg up on the competition.<\/p>\n<p>Pfizer is way behind the GLP-1 pack<\/p>\n<p>Pfizer has a problem when it comes to <a data-ylk=\"slk:GLP-1 weight-loss drugs;elm:context_link;itc:0;sec:content-canvas;\" href=\"https:\/\/www.fool.com\/investing\/how-to-invest\/stocks\/glp-1-stocks\/?utm_source=AolDailyFinance&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=d6626e6e-0a62-4933-bc91-e866f8028863\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">GLP-1 weight-loss drugs<\/a>. Novo Nordisk (NYSE: NVO) was the first to market with its Wegovy shot. Eli Lilly&#8217;s (NYSE: LLY) Zepbound and Mounjaro came out next, but proved more effective and quickly became the industry-leading GLP-1 weight-loss drugs. Pfizer gave up on its own option and was forced to go back to the drawing board by acquiring a company with a more attractive GLP-1 drug candidate.<\/p>\n<p>Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a &#8220;Double Down&#8221; signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same &#8220;Total Conviction&#8221; signal is flashing for a company 1\/100th the size of Nvidia. <a data-ylk=\"slk:Continue \u00bb;elm:context_link;itc:0;sec:content-canvas;\" href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=9756e2f2-9d8e-411d-a2de-dd13e9607785&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fa-sa-dd-total-conviction%3Faid%3D11123%26source%3Disaediica0000078%26ftm_cam%3Dsa-dd-4%26ftm_veh%3Dtop_incontent_pitch_feed_partner%26ftm_pit%3D19478&amp;utm_source=AolDailyFinance&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=d6626e6e-0a62-4933-bc91-e866f8028863\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">Continue \u00bb<\/a><\/p>\n<p><img alt=\"Weight loss drugs in a box.\" loading=\"lazy\" width=\"960\" height=\"640\" decoding=\"async\" data-nimg=\"1\" class=\"standard-img w-full w-full h-auto\" style=\"color:transparent\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/07\/https:\/\/media.zenfs.com\/en\/aol_the_motley_fool_392\/f6a7791c2d94d4ec83dc63fab79cab10.jpeg\"\/><\/p>\n<p>Weight loss drugs in a box.<\/p>\n<p>Image source: Getty Images.<\/p>\n<p>While Novo Nordisk and Eli Lilly are now competing with each other with GLP-1 pills, Pfizer is still trying to get a GLP-1 drug out the door. But it has an ace up its sleeve. The company&#8217;s Berobenatide is taken monthly, compared with competitors&#8217; weekly injections or the daily pills they are now selling. Taking a medication roughly 12 times a year could materially increase adherence rates.<\/p>\n<p>Pfizer&#8217;s GLP-1 drug isn&#8217;t on the market yet<\/p>\n<p>Like all <a data-ylk=\"slk:pharmaceutical companies;elm:context_link;itc:0;sec:content-canvas;\" href=\"https:\/\/www.fool.com\/investing\/stock-market\/market-sectors\/healthcare\/pharmaceutical-stocks\/?utm_source=AolDailyFinance&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=d6626e6e-0a62-4933-bc91-e866f8028863\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">pharmaceutical companies<\/a>, Pfizer must go through the approval process before it can market Berobenatide. And while the latest update from the company is from a phase three trial, it still has a lot more work to do before it can start competing with Eli Lily and Novo Nordisk. So investors have to take the update with a grain of salt. However, it appears that Berobenatide provides similar or better weight-loss benefits to competing GLP-1 drugs.<\/p>\n<p>Similar results and a less frequent medication regimen could help Pfizer become a main player in the GLP-1 space, even though it is late to the party. That said, Novo Nordisk and Eli Lilly aren&#8217;t exactly sitting around doing nothing, so more GLP-1 developments are likely from this pair, as well. Still, obesity is a problem that affects a material number of people, so there&#8217;s likely room for multiple drugs. Consumers and medical providers will select the ones that best serve their unique needs.<\/p>\n<p>In other words, don&#8217;t give up on Pfizer because it doesn&#8217;t have a GLP-1 drug just yet. Given the positive update on Berobenatide, it could just be a matter of time before it does, offering consumers a drug regimen that&#8217;s easier to adhere to.<\/p>\n<p>Should you buy stock in Pfizer right now?<\/p>\n<p>Before you buy stock in Pfizer, consider this:<\/p>\n<p>The Motley Fool Stock Advisor analyst team just identified what they believe are the <a data-ylk=\"slk:10 best stocks;elm:context_link;itc:0;sec:content-canvas;\" href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=5e43c8db-b355-4a1f-a4d0-ef5c4c0774c0&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-sa-bbn-dyn-headline%3Faid%3D8867%26source%3Disaeditxt0001178%26company%3DPfizer%26ftm_cam%3Dsa-bbn-evergreen%26ftm_veh%3Darticle_pitch_feed_partners%26ftm_pit%3D18725&amp;utm_source=AolDailyFinance&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=d6626e6e-0a62-4933-bc91-e866f8028863\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">10 best stocks<\/a> for investors to buy now\u2026 and Pfizer wasn&#8217;t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n<p>Consider when Netflix made this list on December 17, 2004&#8230; if you invested $1,000 at the time of our recommendation, you&#8217;d have $407,004!* Or when Nvidia made this list on April 15, 2005&#8230; if you invested $1,000 at the time of our recommendation, you&#8217;d have $1,244,599!*<\/p>\n<p>Now, it&#8217;s worth noting Stock Advisor&#8217;s total average return is 924% \u2014 a market-crushing outperformance compared to 210% for the S&amp;P 500. Don&#8217;t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n<p><a data-ylk=\"slk:See the 10 stocks \u00bb;elm:context_link;itc:0;sec:content-canvas;\" href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=5e43c8db-b355-4a1f-a4d0-ef5c4c0774c0&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-sa-bbn-dyn-headline%3Faid%3D8867%26source%3Disaeditxt0001178%26company%3DPfizer%26ftm_cam%3Dsa-bbn-evergreen%26ftm_pit%3D18725%26ftm_veh%3Darticle_pitch_feed_partners%26company%3DPfizer&amp;utm_source=AolDailyFinance&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=d6626e6e-0a62-4933-bc91-e866f8028863\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">See the 10 stocks \u00bb<\/a><\/p>\n<p>*Stock Advisor returns as of July 10, 2026.<\/p>\n<p><a data-ylk=\"slk:Reuben Gregg Brewer;elm:context_link;itc:0;sec:content-canvas;\" href=\"https:\/\/www.fool.com\/author\/2110\/\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">Reuben Gregg Brewer<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly, Novo Nordisk, and Pfizer. The Motley Fool has a <a data-ylk=\"slk:disclosure policy;elm:context_link;itc:0;sec:content-canvas;\" href=\"https:\/\/www.fool.com\/legal\/fool-disclosure-policy\/\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">disclosure policy<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Key Points Pfizer has regrouped in the GLP-1 space and is now working on a long-acting drug option.&hellip;\n","protected":false},"author":2,"featured_media":127386,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[276,272,278,4131,277],"class_list":["post-127385","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-eli-lilly","tag-novo-nordisk","tag-nyse","tag-pfizer","tag-weight-loss-drugs"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116898571741224392","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/127385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=127385"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/127385\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/127386"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=127385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=127385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=127385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}